Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.25, Zacks reports.
Kiora Pharmaceuticals Price Performance
KPRX stock opened at $3.25 on Friday. The firm has a market capitalization of $9.89 million, a P/E ratio of -1.12 and a beta of -0.67. Kiora Pharmaceuticals has a 52-week low of $2.51 and a 52-week high of $5.55. The company’s 50 day simple moving average is $3.04 and its 200-day simple moving average is $3.36.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Kiora Pharmaceuticals in a report on Friday, March 28th.
Kiora Pharmaceuticals Company Profile
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Read More
- Five stocks we like better than Kiora Pharmaceuticals
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Constellation Powers Up With Reinforced AI Data Center Strategy
- Want to Profit on the Downtrend? Downtrends, Explained.
- Top Analyst-Rated Healthcare Stocks to Watch Now
- Investing in Travel Stocks Benefits
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
